The Next Generation Biotech Media
The B.1.351 coronavirus variant originally identified in South Africa can break through the protection conferred by Pfizer/BioNTech’s mRNA vaccine, Israeli scientists have found. A team from Tel Aviv University and …
Read More
As the pandemic rages, spreads, and mutates, the demands on biopharma for treatments and the infrastructure built for disease response are intensifying rapidly. The standard technique used for SARS-CoV-2 detection …
Read More
India has identified a new “double mutant” variant of SARS-CoV-2, as the country struggles to avert another full-fledged lockdown and contain a spike in cases that are fanning fears of …
Read More
It is no secret that Japan has lagged behind the COVID-19 vaccine race. With only three vaccines manufactured by local pharmaceutical companies advancing to clinical trials, Japan has relied mostly …
Read More
As the US continues to religiously vaccinate its population with the three approved vaccines amidst growing viral variants, a fourth one seems to be on its way. In a major …
Read More
Image Source: Yoshihide Suga’s Twitter Account On March 12th, leaders of the Quad’s member countries came together in a virtual meet to discuss the strategy to counter China’s influence in …
Read More
Japan initiated its COVID-19 vaccination program as early as mid-February with the Pfizer/BioNTech vaccine. However, it has only managed to administer just 46,500 doses in three weeks, which is about …
Read More
In a first major success for Vir and GSK after a setback just days ago, the duo announced on March 11th that an independent monitoring committee has found their COVID-19 …
Read More
Eli Lilly and Co. announced on March 10th that its combination antibody therapy of bamlanivimab and etesevimab reduced COVID-19 hospitalization risks and deaths by 87% in the Phase 3 BLAZE-1 …
Read More
A month and a half ago, US pharma giant Merck announced its decision to withdraw from the vaccine race as two of its candidates disappointed with unimpressive outcomes. Early trial …
Read More